Agenus Gets $15.1 Million Milestone Payment for Shingrix Sales
March 10 2020 - 09:54AM
Dow Jones News
By Chris Wack
Agenus Inc. on Tuesday reported the triggering of a $15.1
million milestone payment from HealthCare Royalty Partners based on
sales of GlaxoSmithKline's Shingrix vaccine exceeding $2 billion in
2019.
Agenus said its proprietary QS-21 Stimulon is a key component in
GlaxoSmithKline's Shingrix vaccine, which has generated sales
exceeding $2.3 billion in its second year after launch.
Agenus said it is due another milestone amounting to $25.5
million if Shingrix sales exceed $2.75 billion over four
consecutive quarters before 2026.
Agenus shares were up 6% to $2.49 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 10, 2020 09:39 ET (13:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024